The phase III GY004 trial examining primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer failed to meet its primary endpoint of progression-free survival.
The trial was conducted by NRG Oncology. AstraZeneca and Merck sponsor the trial.
The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in progression-free survival with cediranib in combination with Lynparza vs. platinum-based chemotherapy.
Cediranib is an investigational oral vascular endothelial growth factor receptor inhibitor.
“Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” Jose Baselga, executive vice president of oncology R&D, AstraZeneca, said in a statement.
The safety and tolerability profiles observed in GY004 were generally consistent with those known for each medicine.
